PBM
CAPR icon

Propel Bio Management’s Capricor Therapeutics CAPR Stock Holding History

Propel Bio Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-70,000
Closed -$695K – 17
2025
Q2 		$695K Buy
+70,000
New +$739K 0.84% 11

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DCM
DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Propel Bio Management's CAPR Position: Q3 2025 in Review

Propel Bio Management sold out of Capricor Therapeutics (CAPR) in Q3 2025, closing a stake of 70,000 shares — an estimated $695K sold.

Propel Bio Management first reported a position in CAPR in Q2 2025 and held it in 1 quarter. The position peaked at $695K in Q2 2025. 115 funds tracked by Wall St. Rank hold CAPR as of Q3 2025.

  • Propel Bio Management reported no remaining Capricor Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Propel Bio Management sold 70,000 Capricor Therapeutics shares in Q3 2025, an estimated $695K.
  • Propel Bio Management first reported a position in Capricor Therapeutics in Q2 2025 and held it in 1 quarter.
  • Propel Bio Management's Capricor Therapeutics position peaked at $695K in Q2 2025.
  • 115 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2025.

Based on Propel Bio Management's 13F filing for Q3 2025, filed 12 Nov 2025.